Strategic Pivot Toward Capital Sales and Operational Efficiency
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
-
Revenue growth was primarily driven by a record quarter for NeuroStar system sales and continued operational improvements within Greenbrook clinics, specifically through revenue cycle management.
-
Management is executing a deliberate shift in the NeuroStar go-to-market strategy, prioritizing capital equipment sales to compete for larger national accounts that were previously inaccessible under the session-based model.
-
Greenbrook's 20% year-over-year revenue growth resulted from better patient qualification, cleaner insurance claims, and the deployment of Skypoint, an AI-enabled coding optimization tool.
-
The company is reallocating a portion of its direct-to-consumer advertising budget toward expanding the Greenbrook field sales team, as internal data suggests field personnel deliver a higher return on patient acquisition costs.
-
NeuroStar's competitive positioning is supported by a 'velocity differentiator,' with management claiming their customers perform almost twice as many treatments per chair compared to the broader competitive landscape.
-
Strategic partnerships, such as the distribution agreement with Wave Neuroscience for PTSD treatment, are intended to expand the clinical applications of the NeuroStar platform beyond major depressive disorder.
2027 Growth Catalysts and Guidance Framework
-
Management expects the revenue mix to continue weighing more heavily toward NeuroStar capital sales versus session revenue as the new sales strategy matures through 2027.
-
The expansion of the Greenbrook field sales team, adding 8 reps to reach a total of 28 by Q1 2027, is expected to contribute meaningfully to growth by the middle of 2027.
-
Future growth assumptions include the anticipated FDA clearance of an accelerated TMS protocol and the commercial launch of Compass Pathways' COMP360 psychedelic therapeutic in the first half of 2027.
-
Full-year 2026 guidance remains unchanged for revenue, while gross margin expectations were narrowed upward to 49-50% based on improved operational discipline.
-
The company continues to target limited to no net cash utilization from operating and investing activities for the second half of 2026.
Operational Milestones and Clinical Insights
-
The company launched the first-ever integration between a TMS system and an electronic health record (EHR) via a partnership with AdvancedMD to reduce practice documentation burdens.
-
A new clinical publication indicated that treatment gaps of up to 13 days do not reduce TMS effectiveness, a finding management believes will encourage more patients to initiate therapy despite busy schedules.
-
Management noted that over half of all NeuroStar units sold in Q3 were capital or lease units, which positively impacted average selling prices and gross margins.
Q&A Strategic Insights
Greenbrook growth drivers and clinic capacity utilization
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
-
Growth was a combination of revenue cycle gains and double-digit growth in Spravato, which management views as a durable business due to its maintenance phase.
-
Clinic occupancy ranges from 25% to 75%, with management focused on moving the bottom quartile higher through the new field sales approach.
Compass Pathways pilot and psychedelic therapy rollout
-
The company will initially use a hub-and-spoke model in key metropolitan areas rather than launching in all 84 Spravato-enabled clinics immediately.
-
Early rollout will focus on 'hand-to-hand combat' regarding payer relations, likely relying on single-case agreements until coverage for psychedelic therapies matures.
Durability of revenue cycle management (RCM) improvements
-
The deployment of AI tools led to a low double-digit improvement in first-month collections and allowed for back-office headcount reduction.
-
Management believes these structural RCM improvements are durable, though future gains may become more modest as the system reaches peak efficiency.
Rationale for shifting marketing spend to field sales
-
Field reps can target specific prescribers using pharma data, whereas direct-to-consumer (DTC) leads often fail to meet the clinical requirement of failing two prior medications.
-
The shift is intended to be cost-neutral, repurposing existing DTC dollars to sponsor more salespeople without increasing overall marketing expenses.
